These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1287 related articles for article (PubMed ID: 19332033)

  • 1. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M; Moloudi R; Arababadi MK; Shamsizadeh A; Javanmardi K
    Brain Res; 2009 May; 1271():121-7. PubMed ID: 19332033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke.
    Allahtavakoli M; Shabanzadeh AP; Sadr SS; Parviz M; Djahanguiri B
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1052-8. PubMed ID: 17042914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia.
    Yang Y; Li Q; Shuaib A
    Exp Neurol; 2000 May; 163(1):39-45. PubMed ID: 10785442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
    Zhao Y; Patzer A; Gohlke P; Herdegen T; Culman J
    Eur J Neurosci; 2005 Jul; 22(1):278-82. PubMed ID: 16029218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
    J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
    Patzer A; Zhao Y; Stöck I; Gohlke P; Herdegen T; Culman J
    Eur J Neurosci; 2008 Nov; 28(9):1786-94. PubMed ID: 18973594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats.
    Ríos C; Nader-Kawachi J; Rodriguez-Payán AJ; Nava-Ruiz C
    Brain Res; 2004 Mar; 999(2):212-5. PubMed ID: 14759500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
    Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
    Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
    Allahtavakoli M; Shabanzadeh A; Roohbakhsh A; Pourshanazari A
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):309-14. PubMed ID: 17910613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.
    Lapchak PA
    Brain Res; 2010 Jan; 1309():136-45. PubMed ID: 19891959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxyresveratrol (trans-2,3',4,5'-tetrahydroxystilbene) is neuroprotective and inhibits the apoptotic cell death in transient cerebral ischemia.
    Andrabi SA; Spina MG; Lorenz P; Ebmeyer U; Wolf G; Horn TF
    Brain Res; 2004 Aug; 1017(1-2):98-107. PubMed ID: 15261105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats.
    Thiyagarajan M; Kaul CL; Sharma SS
    Br J Pharmacol; 2004 Jul; 142(5):899-911. PubMed ID: 15197101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.
    Culman J; Nguyen-Ngoc M; Glatz T; Gohlke P; Herdegen T; Zhao Y
    Exp Neurol; 2012 Dec; 238(2):243-53. PubMed ID: 22995601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke.
    Alonso de Leciñana M; Gutiérrez M; Roda JM; Carceller F; Díez-Tejedor E
    J Neurol Sci; 2006 Sep; 247(2):121-9. PubMed ID: 16797595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
    Sundararajan S; Gamboa JL; Victor NA; Wanderi EW; Lust WD; Landreth GE
    Neuroscience; 2005; 130(3):685-96. PubMed ID: 15590152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke.
    Shabanzadeh AP; Shuaib A; Wang CX
    Brain Res; 2005 Apr; 1042(1):1-5. PubMed ID: 15823246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral administration of carbenoxolone reduces ischemic reperfusion injury in transient model of cerebral ischemia.
    Vakili A; Hosseinzadeh SA; Khorasani MZ
    J Stroke Cerebrovasc Dis; 2009; 18(2):81-5. PubMed ID: 19251182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.
    Candelario-Jalil E; González-Falcón A; García-Cabrera M; León OS; Fiebich BL
    Brain Res; 2004 May; 1007(1-2):98-108. PubMed ID: 15064140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats.
    Wang CX; Ding X; Noor R; Pegg C; He C; Shuaib A
    J Cereb Blood Flow Metab; 2009 Oct; 29(10):1683-94. PubMed ID: 19553906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA.
    Yi JS; Kim YH; Koh JY
    Exp Neurol; 2004 Oct; 189(2):354-60. PubMed ID: 15380485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.